The Effect of Astaxanthin on Endometriosis Patients
Phase 3
Recruiting
- Conditions
- Endometriosis.Endometriosis, unspecifiedN80.9
- Registration Number
- IRCT20220625055274N1
- Lead Sponsor
- Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Female
- Target Recruitment
- 40
Inclusion Criteria
Patients with infertility due to endometriosis stage III or IV confirmed by ultrasound, laparoscopy, or histopathological examination
20 to 40 years old
18.5 < BMI <30 kg / m2
With regular menstrual cycles
Not taking any hormonal medicine, hormonal contraception, or IUD for 3 months before the first biopsy
No pregnancy or breastfeeding since 3 months before the first biopsy
Willingness to participate in the study
Exclusion Criteria
Autoimmune defects, cancer, and diabetes
Chronic infectious diseases
Any anatomical abnormalities in the uterine cavity such as fibroids and polyps
Pregnancy during the intervention
Taking hormonal drugs during the intervention
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method evel of inflammatory cytokines, expression of Wnt/ ß-catenin pathway genes (ß-catenin, GSK-3b, DKK-1, and WNT7a), expression of phosphorylated and dephosphorylated ß-catenin protein. Timepoint: Before and 12 weeks after the intervention. Method of measurement: ELISA, Real-Time PCR, Western Blot.
- Secondary Outcome Measures
Name Time Method